Presentation is loading. Please wait.

Presentation is loading. Please wait.

PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.

Published byAlexandra Garrison Modified over 9 years ago

Similar presentations

Presentation on theme: "PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic."— Presentation transcript:

1 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S. Sabatine, MD, MPH, Kathleen A. Jablonski, PHD,Madeline Murguia Rice, PHD, Judith Hsia, MD, Ragnhild Wergeland, MT,Sverre Landaas, MD, PHD, Jean L. Rouleau, MD, FACC, Michael J. Domanski, MD, FACC, Christian Hall, MD, PHD, Marc A. Pfeffer, MD, PHD, FACC, Eugene Braunwald, MD, FACC, for the PEACE Investigators

2 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Background & Objectives n Background: The prognostic value of B-type natriuretic peptides (BNPs) in low-risk patients with stable coronary artery disease remains unclear. n Objectives: The purpose of this study was to assess 1) the association between BNP and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, 2) the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and 3) their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition.

3 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Methods n Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin- Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. n Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke.

4 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. MV Adjustment n Treatment assignment n Age n Gender n Body mass index n Ejection fraction <50% n Estimated glomerular filtration rate n Current smoking n Total cholesterol n C-reactive protein n History of: hypertension or measured hypertension, myocardial infarction, diabetes, stroke, percutaneous coronary intervention, coronary artery bypass grafting, n Use of: a beta-blocker, lipid-lowering drug, aspirin or an antiplatelet medication, or diuretic. Outcomes were adjusted for:

5 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Association Between BNPs as Continuous Variables and CV Outcomes Outcome BNPNT-proBNP HR (95% CI) * p ValueHR (95% CI) * p Value Cardiovascular mortality 1.28 (1.08–1.51)0.0042.00 (1.69–2.36)<0.001 Fatal/nonfatal MI0.95 (0.83–1.08)0.431.05 (0.93–1.18)0.43 Fatal/nonfatal CHF1.92 (1.61–2.27)<0.0012.81 (2.33–3.38)<0.001 Fatal/nonfatal stroke1.35 (1.10–1.65)0.0031.93 (1.58–2.36)<0.001 * Per 1 SD pg/ml in log BNP and log NT-proBNP, adjusted for randomization status

6 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. NT-ProBNP and CV Death

7 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. NT-ProBNP and Heart Failure

8 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. NT-ProBNP and Stroke

9 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Multivariable Analysis of Association Between BNPs as Continuous Variables and CV Outcomes Outcome BNP NT-ProBNP HR (95% CI) * p ValueHR (95% CI) * p Value Cardiovascular mortality 1.06 (0.87–1.28)0.571.69 (1.38–2.07)<0.001 Fatal/nonfatal MI0.91 (0.77–1.07)0.241.02 (0.87–1.19)0.84 Fatal/nonfatal CHF1.62 (1.32–1.97)<0.0012.35 (1.86–2.98)<0.001 Fatal/nonfatal stroke1.15 (0.91–1.45)0.241.63 (1.26–2.12)<0.001 * Per 1 SD pg/ml in log BNP and NT-proBNP.

10 PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Conclusion In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.

Download ppt "PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic."

Similar presentations

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):1943-1950.

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.

Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,

Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,

The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.

Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.

Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.
Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.

Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,

The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,
ALLHAT 6/5/2006 - 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,

The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,

Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,
6/5/2006 - 1 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Similar presentations

Ads by Google